- SpyGlass Ophthalmics, a Mission Viejo, CA-based ophthalmic therapeutics company, secured $27.5m in Series B financing
- The round led by Vensana Capital with participation from existing investor New Enterprise Associates
- In conjunction with the funding, NEA Principal Dr. Tak Cheung, formerly a board observer, will now joining the SpyGlass board
- The company also intends to use the funds to further advance the development efforts of platform technology
- SpyGlass Ophthalmics focused on the development of novel treatments for chronic ophthalmic diseases
- The technology originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine and spun off-campus post-Series A funding
